New perspectives in the pharmacologic therapy of cardiac arrhythmias.
D000638:Amiodarone / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001073:Aprindine / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D001949:Bretylium Compounds / Q000494:pharmacology; D002319:Cardiovascular System / Q000187:drug effects; D004206:Disopyramide / Q000494:pharmacology; D004594:Electrophysiology; D006321:Heart / Q000502:physiology; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives; D008801:Mexiletine / Q000494:pharmacology; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000188:drug therapy; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D014700:Verapamil / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D008801:Mexiletine; D001073:Aprindine; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D000638:Amiodarone